title: When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.
abstract: Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Common adverse events in clinical trials with crizotinib included visual disorders, nausea-vomiting, diarrhea and elevated transaminases. Less common toxicities are emerging, such as bradycardia and QT interval prolongation. We report on a case of a presyncopal episode which occurred under crizotinib and metoclopramide treatment.
authors.affiliation: Cardiology Unit, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Gallucci
authors.forename: Alfredo
authors.initials: A
authors.lastname: Tartarone
authors.forename: Lucia
authors.initials: L
authors.lastname: Lombardi
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced*; D000077547:Crizotinib; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D008787:Metoclopramide
keywords: cardiotoxicity; crizotinib; drug interactions; metoclopramide; non-small-cell lung cancer